RxDoctor Payments Data

Amanda Sanchez, APRN

Family · Summerville, SCNPI 1891773990

Payments from drug & device makers

$5,377in general payments, 2019–2025

Across 310 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Supernus Pharmaceuticals, Inc.$445
  • Novo Nordisk$380
  • Lilly USA, LLC$380
  • AstraZeneca$332
  • Pfizer$292
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,377 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,582
Medicare patients
203
Services billed
1,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide78$108,882
MounjaroTirzepatide39$69,361
JardianceEmpagliflozin64$57,901
TrulicityDulaglutide43$49,378
VraylarCariprazine Hcl28$42,334
FarxigaDapagliflozin Propanediol37$30,755
RybelsusSemaglutide15$24,861
EliquisApixaban31$22,341
JanuviaSitagliptin Phosphate16$15,243
MyrbetriqMirabegron15$13,958
LinzessLinaclotide14$8,853
SavellaMilnacipran Hcl12$5,502
NexlizetBempedoic Acid/Ezetimibe12$4,928
VyvanseLisdexamfetamine Dimesylate13$4,861
Arnuity ElliptaFluticasone Furoate17$4,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$380$133,74393 claims
Lilly USA, LLCMounjaro, Trulicity$380$118,73982 claims
AbbVieVraylar, Linzess, Savella, Armour Thyroid, Synthroid$1,074$59,877100 claims
Boehringer IngelheimJardiance$146$57,90164 claims
AstraZenecaFarxiga, Symbicort$332$34,57748 claims
PfizerEliquis$292$22,34131 claims
MerckJanuvia$22$15,24316 claims
Astellas Pharma US IncMyrbetriq$17$13,95815 claims
Esperion Therapeutics, Inc.Nexlizet$34$4,92812 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$104$4,86113 claims
GSKArnuity Ellipta$50$4,12217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →